iRadimed Corp. (NASDAQ:IRMD) shares saw unusually-high trading volume on Tuesday . Approximately 136,808 shares were traded during mid-day trading, an increase of 149% from the previous session’s volume of 54,865 shares.The stock last traded at $17.30 and had previously closed at $19.08.

IRMD has been the topic of a number of recent analyst reports. Roth Capital reaffirmed a “buy” rating on shares of iRadimed Corp. in a research report on Tuesday, May 3rd. Zacks Investment Research lowered iRadimed Corp. from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 5th.

The firm has a market capitalization of $183.98 million and a PE ratio of 24.53. The firm’s 50 day moving average is $20.53 and its 200 day moving average is $18.46.

iRadimed Corp. (NASDAQ:IRMD) last posted its earnings results on Friday, July 29th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.21 by $0.03. The firm earned $9.90 million during the quarter, compared to analyst estimates of $9.60 million. iRadimed Corp.’s revenue for the quarter was up 30.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.16 EPS. Analysts forecast that iRadimed Corp. will post $0.92 earnings per share for the current year.

In related news, Director Monty K. Allen sold 2,100 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $20.44, for a total value of $42,924.00. Following the completion of the sale, the director now directly owns 4,375 shares in the company, valued at $89,425. The sale was disclosed in a filing with the SEC, which is available at this link.

A hedge fund recently bought a new stake in iRadimed Corp. stock. Russell Frank Co purchased a new stake in shares of iRadimed Corp. (NASDAQ:IRMD) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 95,112 shares of the company’s stock, valued at approximately $2,675,000. Russell Frank Co owned approximately 0.86% of iRadimed Corp. at the end of the most recent quarter.

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.